InsiderTrades

Form 4 for AMGN Amgen

Accepted 2022-05-09 00:00:00 ET · period of report 2022-05-05 · accession 0001127602-22-013876 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
2022-05-09 2022-05-05 AMGN REESE DAVID M EVP, Research, Development F - Tax $236.10 -575 50.3K -1% -$135.8K

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-05-05 F D 575 $236.10 50,307 D — — (F2) These shares include 897 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. (F1) These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 4,363 RSUs which will vest on 11/2/2022; 1,534 RSUs which will vest on 5/3/2023; 2,325 RSUs which vest in installments of 1,145 on 5/5/2023 and 1,180 on 5/5/2024; 4,006 RSUs which vest in installments of 1,321 on 4/30/2023, 1,322 on 4/30/2024 and 1,363 on 4/30/2025; and 3,897 RSUs which will vest in two installments of 1,286 on 5/2/2024 and 5/2/2025, and one installment of 1,325 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.